TAPERANK
Open the app
UNEXPLAINED MOVE · MOVER · WED OCT 28 2026

Why GMAB rose 21.1% on Oct 28 2026: phase 3 oncology data

GMAB+21.1%on Wed Oct 28 2026

Genmab A/S ADS was up 21.1% on the day at $54.11, ranked #2 on 17.8× its usual five-minute volume, when TapeRank recorded this spike at 10:15 ET during regular hours. TapeRank recorded 2 events for GMAB that day, between 09:45 and 10:15 ET, and each is in the timeline below.

THE DAY ON THE LIST · 2 EVENTS

  1. 09:45 ET
    UNEXPLAINED MOVE · REGULAR

    $51.58 · ▲ 15.5% ON THE DAY · 39.4× 5M RVOL · RANK #2

    UNEXPLAINEDNO FILINGS · RULE

    GMAB is up 3.6% on the day on 14.4x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.

    WHYNo filings or headlines within 24 hours of the move.
    ANALYZED 09:41 ET · 3 MIN AGO · RULE, NO MODEL
    THE ROW AND SESSION LEVELS AT 09:45 ET
    LAST51.58
    DAY▲ 15.5%
    5 MIN▲ 11.45%
    5M RVOL39.4×
    5M $VOL$92.9M
    FLOAT*623.5M
    RANK#2
    SESSIONREGULAR
    VWAP47.66
    HOD51.08
    LOD44.35
    OR HIGH44.86
    OR LOW44.35
    PREV CLOSE44.67
    PM HIGH44.93
    PM LOW44.46
    GAP▼ 0.09%

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

  2. 10:15 ET
    MOVER · REGULAR

    $54.11 · ▲ 21.1% ON THE DAY · 17.8× 5M RVOL · RANK #2

    JUSTIFIEDCONFIDENCE5/5

    GMAB is up 15.0%, with an additional 5.34% surge in five minutes, after reporting statistically significant Phase 3 results for petosemtamab. A 50% reduction in death risk, a positive overall-survival endpoint, and improved response rate are major clinical catalysts that support a sharp repricing.

    WHYA 15% move is substantial but proportionate to a Phase 3 oncology result showing a 50% death-risk reduction and p<0.0001 significance.
    ANALYZED 09:46 ET · 28 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 10:15 ET
    LAST54.11
    DAY▲ 21.1%
    5 MIN▲ 2.15%
    5M RVOL17.8×
    5M $VOL$37.6M
    FLOAT*623.5M
    RANK#2
    SESSIONREGULAR
    VWAP50.69
    HOD54.00
    LOD44.35
    OR HIGH44.86
    OR LOW44.35
    PREV CLOSE44.67
    PM HIGH44.93
    PM LOW44.46
    GAP▼ 0.09%

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

THE SESSION

  • 09:30 ETOpened at $44.63, -0.1% on the previous close of $44.67
  • 09:31 ETRegular-session low, $44.35
  • 14:25 ETRegular-session high, $59.97
  • 15:59 ETLast trade of the regular session, $57.32, +28.3% on the previous close of $44.67
  • Volume: 28.6M shares in regular hours, 5K before the open

GMAB opened nearly flat at $44.63, dipped to $44.35, then surged to $51.58 by 09:45 ET and $54.11 at 10:15 ET. TapeRank tied the move to Genmab’s Phase 3 petosemtamab data, which showed a 50% reduction in death risk, a positive overall-survival result and improved response rate; it also later marked the move unexplained under its rule that found no filings or headlines within 24 hours. The stock reached $59.97 at 14:25 ET and finished at $57.32, up 28.3% from the previous close, with no halts.

WRITTEN WED OCT 28 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list